Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nomlabofusp - Larimar Therapeutics

Next Previous
Drug Profile

Nomlabofusp - Larimar Therapeutics

Alternative Names: CTI 1601; Tat-frataxin; TAT-FXN

Latest Information Update: 11 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Indiana University; Wake Forest University School of Medicine
  • Developer Larimar Therapeutics
  • Class Recombinant fusion proteins
  • Mechanism of Action Frataxin protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Friedreich's ataxia
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Friedreich's ataxia

Most Recent Events

  • 04 Aug 2026 Larimar Therapeutics announces intention to launch Nomlabofusp in the US in mid 2027
  • 04 Aug 2026 Larimar Therapeutics plans a confirmatory phase III trial for Friedreich's ataxia in USA, the European Union, the United Kingdom, Canada and Australia (SC) in third quarter of 2026
  • 29 Jun 2026 Preregistration for Friedreich's ataxia in USA (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top